Ticker
AADI

Price
13.53
Stock movement down
-0.24 (-1.74%)
Company name
Aadi Bioscience Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
283.35M
Ent value
171.19M
Price/Sales
85.68
Price/Book
2.27
Div yield
-
Div growth
-
Growth years
-
FCF payout
-13.20%
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-59.37%
3 year return
-55.41%
5 year return
-
10 year return
-
Last updated: 2022-08-25

DIVIDENDS

AADI does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales85.68
Price to Book2.27
EV to Sales51.77

FINANCIALS

Per share

Loading...
Per share data
Current share count20.94M
EPS (TTM)-5.81
FCF per share (TTM)-1.83

Income statement

Loading...
Income statement data
Revenue (TTM)3.31M
Gross profit (TTM)3.25M
Operating income (TTM)-121.84M
Net income (TTM)-121.34M
EPS (TTM)-5.81
EPS (1y forward)-3.03

Margins

Loading...
Margins data
Gross margin (TTM)98.22%
Operating margin (TTM)-3684.35%
Profit margin (TTM)-3669.28%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash129.85M
Net receivables2.71M
Total current assets135.62M
Goodwill0.00
Intangible assets3.74M
Property, plant and equipment0.00
Total assets142.32M
Accounts payable4.01M
Short/Current long term debt587.00K
Total current liabilities11.51M
Total liabilities17.69M
Shareholder's equity124.63M
Net tangible assets120.89M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-38.17M
Capital expenditures (TTM)161.00K
Free cash flow (TTM)-38.33M
Dividends paid (TTM)5.06M

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-97.36%
Return on Assets-85.26%
Return on Invested Capital-97.24%
Cash Return on Invested Capital-30.72%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open13.94
Daily high13.94
Daily low13.23
Daily Volume104K
All-time high1485.00
1y analyst estimate43.50
Beta-
EPS (TTM)-5.81
Dividend per share-
Ex-div date-
Next earnings date8 Nov 2022

Downside potential

Loading...
Downside potential data
AADIS&P500
Current price drop from All-time high-99.09%-12.18%
Highest price drop-99.22%-56.47%
Date of highest drop11 May 20229 Mar 2009
Avg drop from high-73.60%-11.38%
Avg time to new high65 days12 days
Max time to new high1194 days1805 days
COMPANY DETAILS
AADI (Aadi Bioscience Inc) company logo
Marketcap
283.35M
Marketcap category
Small-cap
Description
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Employees
54
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announce...
September 22, 2022
Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTO...
September 1, 2022
Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, ...
August 10, 2022
Every investor in Aadi Bioscience, Inc. ( NASDAQ:AADI ) should be aware of the most powerful shareholder groups...
August 4, 2022
Aadi Bioscience, Inc. (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, ...
July 28, 2022
LOS ANGELES, June 23, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined c...
June 23, 2022
LOS ANGELES, June 01, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined c...
June 1, 2022
LOS ANGELES, May 31, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined ca...
May 31, 2022
Target tumor reductions observed in advanced malignant PEComa patients harboring TSC1 or TSC2 inactivating alterations regardless of prior mTOR inhibitor exposureLOS ANGELES, May 26, 2022 (GLOBE NEWSW...
May 26, 2022
LOS ANGELES, May 18, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined ca...
May 18, 2022
Next page